Benign Prostatic Hyperplasia - Epidemiology Forecast to 2024 Market Report; Launched via MarketResearchReports.com

Benign prostatic hyperplasia (BPH) is a nonmalignant growth of prostatic tissue that surrounds the urethra, and leads to constriction of the urethral opening, which gives rise to lower urinary tract symptoms (LUTS). BPH is commonly observed in men ages 40 years and above. The diagnosis of BPH is made on clinical basis by the presence of LUTS and benign prostatic enlargement and the absence of any other identifiable causes.

The diagnosed prevalent cases of BPH in the 7MM increased from 16,095,043 cases in 2014 to 18,884,244 cases in 2024, at an annual growth rate (AGR) of 1.73% during the forecast period. Among the 7MM in 2024, the US will have the highest number of diagnosed prevalent cases of BPH, with 6,182,362 diagnosed prevalent cases, whereas Spain will have the lowest number, with 1,599,508 diagnosed prevalent cases. In the 5EU, Germany will have the highest number of diagnosed prevalent cases of BPH in 2024, with 2,512,517 diagnosed prevalent cases, and Spain will have the lowest number, with 1,599,508 diagnosed prevalent cases.

The epidemiological analysis provides a country-specific forecast for the diagnosed prevalent cases of BPH in the 7MM during 2014-2024.To construct the 10-year epidemiological forecast for the diagnosed prevalent cases of BPH in the 7MM, Publisher epidemiologists used data available from population based studies in the 7MM. For the US, Publisher epidemiologists used data available from a study that provided a nationally representative number of diagnosed BPH cases in the US men, which was further segmented into the age-specific diagnosed BPH cases. Publisher epidemiologists used the data available from population based studies in the UK and Italy to calculate the diagnosed prevalence of BPH in the 5EU. Due to lack of data on the diagnosed prevalence of BPH in Japan, Publisher epidemiologists used a study from Korea and applied the age-specific distribution of histological prevalence from a US study to calculate the age-specific diagnosed prevalence of BPH in Korea, and then used it as proxy for Japan.

Scope

• The benign prostatic hyperplasia (BPH) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for Benign Prostatic Hyperplasia in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of BPH segmented by age (10-year intervals starting at ages 40 years and ending at =85 years). The diagnosed prevalent cases of BPH were segmented into mild, moderate, and severe categories as per the IPSS criteria defined by the American Urological Association.
• The BPH epidemiology report is were written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving the global BPH market.
• Quantify patient populations in the global BPH market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and disease severity category that present the best opportunities for BPH therapeutics in each of the markets covered.

Spanning over 28 pages “EpiCast Report: Benign Prostatic Hyperplasia - Epidemiology Forecast to 2024” report covers Introduction, Epidemiology, Appendix

For further information on this report, please visit- http://mrr.cm/oYo

Find all Diseases Report at: http://www.marketresearchreports.com/diseases